Clinical Trial Detail

NCT ID NCT02725489
Title Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Mary Crowley Medical Research Center
Indications

ovarian cancer

cervical cancer

endometrial cancer

breast cancer

fallopian tube cancer

uterine cancer

peritoneum cancer

Therapies

Durvalumab + FANG vaccine

Age Groups: senior adult

No variant requirements are available.